热门资讯> 正文
Bright Minds定价1.75亿美元股票发行
2026-01-08 15:29
- Bright Minds Biosciences (DRUG) priced its previously announced public offering of ~1.95M shares at a price of $90.00 per share.
- Gross proceeds are expected to be ~$175M.
- The underwriters have a 30-day option to purchase up to an additional 291,750 shares.
- The net proceeds will be used to fund future clinical trials for the company’s drug candidates, including for absence seizures, DEE, and Prader-Willi Syndrome, as well as initiation of phase 1 clinical drug trials for BMB-105, and additional research and development work on earlier phase programs, as well as for general corporate and working capital purposes.
- The closing of the offering is expected to occur on January 9, 2026.
- The stock price traded ~1% lower on Thursday during pre-market hours of trading.
More on Bright Minds Biosciences
- Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating
- Bright Minds Biosciences launches $100 million public offering
- Bright Minds gains on mid-stage trial win for lead asset
- Seeking Alpha’s Quant Rating on Bright Minds Biosciences Inc.
- Historical earnings data for Bright Minds Biosciences Inc.
推荐文章
港股周报 | 超配中国！高盛称中国股市26年大涨15%至20%；阿里称坚定加大淘宝闪购投入
2026年展望 | 智能驾驶元年或开启！特斯拉Robotaxi引爆赛道，港美股哪些标的值得布局？
美股机会日报 | 重磅大考！“非农+关税裁决”今夜同台亮相；Meta宣布将投资核电厂，OKLO等核电股盘前飙升！
一周财经日历 | 美国12月CPI携手“恐怖数据”来袭；华尔街大行启动Q4财报季，台积电财报或炸场！4只港股新股即将上市
一周IPO | 吃大肉！本周六只新股上市大涨，MINIMAX暴涨109%；BBSB INTL孖展倍数超8900倍，位列史上第三
财报前瞻 | 台积电Q4营收料冲破万亿新台币！大摩喊话绩前买入，2026年股价还能“继续飞”吗？
MiniMax上市首日涨超60%，阿里、米哈游等投资方“躺赢”
特朗普大赞英特尔及CEO陈立武 股价盘后上涨
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
